Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity.
about
Allogeneic tumor cell vaccines: the promise and limitations in clinical trialsAnti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefitsThe Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevancePhylogenetic expression of Galalpha1-4Gal on avian glycoproteins: glycan differentiation inscribed in the early history of modern birdsImmune and gene therapy for melanoma, and the immunobiology of melanoma.Combination immunotherapy for high-risk resected and metastatic melanoma patientsIncreased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopesBridging innate and adaptive antitumor immunity targeting glycans.Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cellsIn pursuit of xenoreactive antibodies: where has it gotten us?In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids.Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinomaThe sweet side of tumor immunotherapy.Adjuvant therapy for pancreas adenocarcinoma.Discovery of the natural anti-Gal antibody and its past and future relevance to medicine.Adenovirus-mediated expression of pig alpha(1, 3) galactosyltransferase reconstructs Gal alpha(1, 3) gal epitope on the surface of human tumor cells.Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity.Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria.Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma.A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer.In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene.Autoantibodies to cytokines.Non-depleting anti-CD4, but not anti-CD8, antibody induces long-term survival of xenogeneic and allogeneic hearts in alpha1,3-galactosyltransferase knockout (GT-Ko) mice.MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral
P2860
Q26852333-9D5CFCC4-C1B0-4457-8C65-CB8C7CB88FD6Q27021788-F8BCBEF3-8F77-47E2-9C84-B0708D5BA2EBQ28755302-E311BDE5-EB97-4F4B-B4A9-A53A18EA0D35Q28775790-1B6E204D-0DC9-45ED-9607-91304C37F8D2Q33706946-18FC3478-D0C8-4635-BDFE-BFCDA19CB95EQ33737498-D4DE787B-8A32-4124-BC36-4A438E32852CQ33837215-43C86E16-DCA3-4CCE-BA9D-ECAF9E081F0AQ33960021-2EB73E3B-F949-423E-AED5-21EF33A157C1Q35638775-7C423B64-B283-46B2-B6B2-242CD2DD3BE8Q36201684-B9D186E6-E021-498C-829E-AA1C0A1F96CDQ36331013-49D20DC2-C255-495E-BBD1-02C09842162DQ36758192-B34F04A3-C447-4E9C-B3F4-8D747D804B74Q37191059-8DAF1156-46A9-416D-8DEA-454BB848BD00Q38031282-03EA8CB2-932A-4D6E-ABDB-ECE9BE783855Q38034110-9B57B56A-BE9A-48DC-944D-9F38A637D48AQ38098230-5EA05466-B26E-422D-8FCC-A2A65E14E7DEQ38299022-E5DC1E1F-8F09-4E96-ABBD-054E057D5E02Q38356968-796AC100-CD5D-47F3-B9A8-611B705E346EQ38361951-75AFB218-8AD5-46BA-86CE-9233EF32353DQ41495119-009AC176-61DB-4E13-A3A4-A4D76479CEA1Q42129387-20FE7872-30F5-4433-9833-F163F2FF8659Q43214125-73249AC0-329D-4D1A-9B10-5C6A5CD3A084Q45861534-B68D79B8-3DE1-4745-B29D-F2EC91ED4191Q45882698-29984471-62E5-4080-A807-0DB0B7007A05Q48005345-AFD465FD-D5A9-4968-A052-1904E2842D6AQ54029734-FC03AE17-4363-4BEE-AB58-43185579235FQ57594342-EC2D267A-E207-495B-B4F5-0CAAF66C8585
P2860
Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Natural anti-Gal antibody as a ...... tumor vaccine immunogenicity.
@en
type
label
Natural anti-Gal antibody as a ...... tumor vaccine immunogenicity.
@en
prefLabel
Natural anti-Gal antibody as a ...... tumor vaccine immunogenicity.
@en
P1433
P1476
Natural anti-Gal antibody as a ...... tumor vaccine immunogenicity.
@en
P2093
P304
P356
10.1016/S0167-5699(97)80024-2
P577
1997-06-01T00:00:00Z